Issue 1/2010
Content (7 Articles)
Should Financial Incentives be Used to Differentially Reward ‘Me-Too’ and Innovative Drugs?
Brita Pekarsky
Adverse Drug Interactions
Ryan Mayhew, June M. McKoy, Thanh Ha Luu, Isaac Lopez, Melissa Frick, Charles L. Bennett
The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
Fred J. Hellinger, William E. Encinosa
Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma
Eric Deconinck, Houda Miadi-Fargier, Claude Le Pen, Pauline Brice
Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
Virginia M. Rosen, Douglas C. A. Taylor, Hemangi Parekh, Ankur Pandya, David Thompson, Andreas Kuznik, David D. Waters, Michael Drummond, Milton C. Weinstein
A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
Lisa M. Meckley, James M. Gudgeon, Jeffrey L. Anderson, Marc S. Williams, David L. Veenstra